Skip to main content

Table 1 The clinical characteristics of LMNA mutation carriers.

From: Late gadolinium enhanced cardiovascular magnetic resonance of lamin A/C gene mutation related dilated cardiomyopathy

LMNA

carrier

Gender

(male/female)

Age

(years)

Mutation

Symptoms

Cardiac medication

Rhythm

PR (upper

limit 200 ms)

QRS (upper

limit100 ms)

q-waves,

low r-waves

1

M

42

ser143pro

vertigo

ACE-blocker

fa

-

158

V1-3 QS

2

F

54

ser143pro

dyspnea

extrasystolia

none

sr

276

124

no

3

F

30

ser143pro

none

none

sr

236

96

no

4

M

32

ser143pro

none

none

sr

176

112

no

5

M

18

ser143pro

palpitation

none

sr

176

96

no

6

F

18

ser143pro

none

none

sr

164

108

no

7

F

29

ser143pro

palpitation

none

sr

182

92

no

8

M

39

T1085Xdeletion

none

none

sr

322

106

no

9

M

25

ala132pro

paroxysmal

flutter

warfarin, bisoprolol

sr

176

112

no

10

F

52

ala132pro

extrasystolia

none

sr

276

92

no

11

M

29

arg190trp

palpitation

none

sr

160

100

no

12

F

32

arg190trp

palpitation

none

sr

140

84

no

13

F

64

arg190trp

vertigo

warfarin, bisoprolol, digoxin

fa

-

84

Low r-waves V1-4

14

M

58

arg190trp

dyspnea

NYHA 2

warfarin, AT-receptor blocker, diuretic, betablocker

sr

208

100

QS V1

15

M

43

ser143pro

none

none

sr

328

90

no

16

F

35

ser143pro

extrasystolia

none

sr

224

76

no

17

F

39

ser143pro

none

none

sr

254

114

QS V1-2

  1. This table demonstrates patients age, gender, type of lamin A/C mutation, symptoms, medications, heart rhythm and possible abnormalities in ECG (prolonged PR interval, widened QRS complex or presence on q-waves or low t-waves).
  2. NYHA = New York Heart Association classification; sr = sinus rhythm, fa = atrial fibrillation